Agios Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Agios Pharmaceuticals hat ein Gesamteigenkapital von $886.8M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $1.0B bzw. $120.4M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$776.93m |
| Equity | US$811.02m |
| Total liabilities | US$126.10m |
| Total assets | US$937.12m |
Recent financial health updates
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Recent updates
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced
Sep 07Agios submits mitapivat application in U.S. for pyruvate kinase deficiency
Jun 21Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
May 13Agios Pharmaceuticals Q1 2021 Earnings Preview
Apr 28Financial Position Analysis
Kurzfristige Verbindlichkeiten: AGIODie kurzfristigen Aktiva des Unternehmens ($704.4M) übersteigen seine kurzfristigen Passiva ($58.4M).
Langfristige Verbindlichkeiten: AGIODie kurzfristigen Vermögenswerte des Unternehmens ($704.4M) übersteigen seine langfristigen Verbindlichkeiten ($62.0M).
Debt to Equity History and Analysis
Verschuldungsgrad: AGIO ist schuldenfrei.
Schulden abbauen: AGIO hatte vor 5 Jahren keine Schulden.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stabile Start- und Landebahn für Bargeld: AGIO auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.
Vorhersage Cash Runway: AGIO verfügt über eine ausreichende Liquiditätsreserve für 2.8 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 0.4% pro Jahr abnimmt.